---
title: "Weekly Recap | Ginkgo Bioworks +8.98%, a sharp V-shaped week"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296667695.md"
description: "Ginkgo Bioworks rallied 8.98% this week to close at $7.40, handily outpacing the S&P 500, which slid 1.43% over the same stretch. The week played out in a sharp V-shape: after dipping to a near-term low of $6.47 on Tuesday (18 August), the stock staged a powerful reversal on Wednesday (19 August), surging to an intraday high of $7.749 on the heaviest volume of the week. The second half of the session saw some giveback, but the name stabilised on Friday (21 August) to finish at $7.40."
datetime: "2026-08-22T04:46:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296667695.md)
  - [en](https://longbridge.com/en/news/296667695.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296667695.md)
generator: "portal-rs"
---

# Weekly Recap | Ginkgo Bioworks +8.98%, a sharp V-shaped week

## The Week

Ginkgo Bioworks rallied 8.98% this week to close at $7.40, handily outpacing the S&P 500, which slid 1.43% over the same stretch. The week played out in a sharp V-shape: after dipping to a near-term low of $6.47 on Tuesday (18 August), the stock staged a powerful reversal on Wednesday (19 August), surging to an intraday high of $7.749 on the heaviest volume of the week. The second half of the session saw some giveback, but the name stabilised on Friday (21 August) to finish at $7.40. Weekly amplitude hit 19.09%, and average daily volume came in roughly 29.58% above the 60-day median, signalling a clear pickup in activity despite the absence of any company-specific news or filings during the window.

## Analyst Ratings

Three brokers cover Ginkgo Bioworks, and the current consensus is split: one rates it hold, one rates it under, and one rates it sell, landing at a consensus recommendation of ‘sell’. The consensus target price is $7.00, which sits roughly 5.41% below the latest close of $7.40. Individual targets range from a low of $5.00 to a high of $9.00, a wide spread that suggests analysts are still wrestling with how to value the synthetic-biology platform. Within the life sciences tools and services industry, Ginkgo’s ranking stands at 40 out of 53 names, placing it in the lower tier of the peer group.

## The Week Ahead

A busy macro calendar awaits next week, with the focus squarely on US housing and consumer confidence data. On 25 August (Tuesday), the FHFA house price index, the Case Shiller 20-city composite, and new home sales figures will be released alongside the Conference Board’s consumer confidence index and the Richmond Fed composite index. These readings will offer fresh clues on the economy’s trajectory. For Ginkgo, which has no earnings or corporate events on the horizon, sentiment is likely to remain tethered to the broader small- and mid-cap biotech tape, making the macro pulse the key thing to watch.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [DNA.US](https://longbridge.com/en/quote/DNA.US.md)

## Related News & Research

- [This Small-Cap Stock Announced a Deal With Eli Lilly. Then Its Shares Doubled](https://longbridge.com/en/news/300952376.md)
- [‘Open Your Eyes,’ Says Top Investor About Oracle Stock](https://longbridge.com/en/news/301160283.md)
- [Marvell Now Sees as Much as $90 Billion in Annual Sales by Fiscal 2031. Here's Why It's a Chip Stock to Buy.](https://longbridge.com/en/news/301114413.md)
- [Palantir vs. Oracle – Why Daniel Ives Says Buy One, Hold the Other](https://longbridge.com/en/news/301155464.md)
- [Broadcom's AI Revenue Is Growing at 221%. Here's Why Custom Chips Could Be a Bigger Business Than GPUs.](https://longbridge.com/en/news/301141333.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**